In Vitro Efficacy of Corifungin against Acanthamoeba castellanii Trophozoites and Cysts

被引:20
作者
Debnath, Anjan [1 ]
Tunac, Josefino B. [2 ]
Silva-Olivares, Angelica [3 ]
Galindo-Gomez, Silvia [3 ]
Shibayama, Mineko [3 ]
McKerrow, James H. [1 ]
机构
[1] Univ Calif San Francisco, Ctr Discovery & Innovat Parasit Dis, San Francisco, CA 94143 USA
[2] Acea Biotech, San Francisco, CA USA
[3] CINVESTAV, IPN, Dept Infect & Mol Pathogenesis, Mexico City 14000, DF, Mexico
关键词
FREE-LIVING AMEBAS; AMPHOTERICIN-B; BALAMUTHIA-MANDRILLARIS; OPPORTUNISTIC AMEBAS; NAEGLERIA-FOWLERI; MILTEFOSINE; KERATITIS; ENCEPHALITIS; SPP; EPIDEMIOLOGY;
D O I
10.1128/AAC.02254-13
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Painful blinding keratitis and fatal granulomatous amebic encephalitis are caused by the free-living amebae Acanthamoeba spp. Several prescription eye medications are used to treat Acanthamoeba keratitis, but the infection can be difficult to control because of recurrence of infection. For the treatment of encephalitis, no single drug was found useful, and in spite of the use of a combination of multiple drugs, the mortality rate remains high. Therefore, efficient, novel drugs are urgently needed for the treatment of amebic keratitis and granulomatous amebic encephalitis. In this study, we identified corifungin, a water-soluble polyene macrolide, as amebicidal. In vitro, it was effective against both the trophozoites and the cysts. Transmission electron microscopy of Acanthamoeba castellanii incubated with corifungin showed the presence of swollen mitochondria, electron-dense granules, degeneration of cytoplasm architecture, and loss of nuclear chromatin structure. These changes were followed by lysis of amebae. Corifungin also induced the encystment process of A. castellanii. There were alterations in the cyst cell wall followed by lysis of the cysts. Corifungin is a promising therapeutic option for keratitis and granulomatous amebic encephalitis.
引用
收藏
页码:1523 / 1528
页数:6
相关论文
共 32 条
[1]   Successful Treatment of Disseminated Acanthamoeba sp Infection with Miltefosine [J].
Aichelburg, Alexander C. ;
Walochnik, Julia ;
Assadian, Ojan ;
Prosch, Helmut ;
Steuer, Andrea ;
Perneczky, Gedeon ;
Visvesvara, Govinda S. ;
Aspoeck, Horst ;
Vetter, Norbert .
EMERGING INFECTIOUS DISEASES, 2008, 14 (11) :1743-1746
[2]  
Baginski M, 2005, ACTA BIOCHIM POL, V52, P655
[3]   In Vitro Efficacies of Clinically Available Drugs against Growth and Viability of an Acanthamoeba castellanii Keratitis Isolate Belonging to the T4 Genotype [J].
Baig, Abdul Mannan ;
Iqbal, Junaid ;
Khan, Naveed Ahmed .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (08) :3561-3567
[4]   A novel mechanism for an old drug: Amphotericin B in the treatment of visceral leishmaniasis [J].
Chattopadhyay, Amitabha ;
Jafurulla, Md .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2011, 416 (1-2) :7-12
[5]   Corifungin, a New Drug Lead against Naegleria, Identified from a High-Throughput Screen [J].
Debnath, Anjan ;
Tunac, Josefino B. ;
Galindo-Gomez, Silvia ;
Silva-Olivares, Angelica ;
Shibayama, Mineko ;
McKerrow, James H. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (11) :5450-5457
[6]   MICROBIAL-CONTAMINATION OF CONTACT-LENS CARE SYSTEMS [J].
DONZIS, PB ;
MONDINO, BJ ;
WEISSMAN, BA ;
BRUCKNER, DA .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1987, 104 (04) :325-333
[7]   A novel injectable water-soluble amphotericin B-arabinogalactan conjugate [J].
Falk, R ;
Domb, AJ ;
Polacheck, I .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (08) :1975-1981
[8]   Acanthamoeba keratitis: Risk factors and outcome [J].
Illingworth, CD ;
Cook, SD ;
Karabatsas, CH ;
Easty, DL .
BRITISH JOURNAL OF OPHTHALMOLOGY, 1995, 79 (12) :1078-1082
[9]   Acanthamoeba:: biology and increasing importance in human health [J].
Khan, Naveed Ahmed .
FEMS MICROBIOLOGY REVIEWS, 2006, 30 (04) :564-595
[10]   Acanthamoeba spp. as agents of disease in humans [J].
Marciano-Cabral, F ;
Cabral, G .
CLINICAL MICROBIOLOGY REVIEWS, 2003, 16 (02) :273-+